Bagsværd, Denmark and Mountain View, California, 9 January 2017
Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk’s deep knowledge of diabetes with Glooko’s digital platform and data analytics expertise.

Building on Glooko’s mobile and web platforms, the companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. The partnership’s joint offerings will also assist healthcare professionals to engage and manage patients with the aid of population-wide data reporting. By integrating these offerings within its Digital Health Platform developed with IBM Watson Health, Novo Nordisk aims to generate increasingly valuable insights into diabetes management and treatment outcomes.
Commenting on the agreement, Christian Kanstrup, senior vice president, Strategy, Access & Marketing, Novo Nordisk said: “We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control. Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”

Glooko is a leading population health platform for diabetes management and enables people with diabetes to more easily track and better manage their condition using mobile, web and cloud technology. Glooko’s award-winning mobile health app enables individuals to synchronise their data from a majority of the world’s most popular diabetes and exercise devices including blood glucose meters. Glooko’s population health application enables care teams to remotely support people with diabetes and aims to improve patient satisfaction and outcomes at a lower cost.

“Glooko’s partnership with Novo Nordisk aims to empower tens of millions of patients with digital tools to make diabetes management easier”, said Rick Altinger, Glooko CEO. “We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world.”

 

<strong>About Novo Nordisk</strong>

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 75 countries and markets its products in more than 180 countries. For more information, visit <a href=”http://novonordisk.com” target=”_blank”>novonordisk.com</a>, <a href=”http://www.facebook.com/novonordisk”>Facebook</a>, <a href=”http://www.twitter.com/novonordisk”>Twitter</a>, <a href=”http://www.linkedin.com/company/novo-nordisk”>LinkedIn</a>, <a href=”http://www.youtube.com/novonordisk”>YouTube</a>

<strong>About Glooko</strong>

Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Over 4,800 health systems in 27 countries use Glooko’s FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes and to enable diabetes population health for providers. Glooko seamlessly syncs with the world’s most popular diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. For more information visit: <a href=”https://glooko.com/”>glooko.com</a>, <a href=”https://www.facebook.com/Glooko/”>Facebook</a>, <a href=”https://twitter.com/GlookoInc”>Twitter</a>, <a href=”https://www.linkedin.com/company/Glooko”>LinkedIn</a>, <a href=”https://www.youtube.com/user/GlookoInc”>YouTube</a>.

 

<strong>Further information</strong>

<em>Novo Nordisk Media:</em>

Adam Pittard                        +45 3075 5056       <a href=”mailto:[email protected]” target=”_blank”>[email protected]</a>

Ken Inchausti (US)             +1 609 786 8316    <a href=”mailto:[email protected]”>[email protected]</a>

 

<em>Glooko Media:</em>

Vikram Singh                       +1 650 720 5310    <a href=”mailto:[email protected]”>[email protected]</a>

 

<em>Novo Nordisk Investors:</em>

Peter Hugreffe Ankersen   +45 3075 9085      <a href=”mailto:[email protected]”>[email protected]</a>

Melanie Raouzeos               +45 3075 3479      <a href=”mailto:[email protected]”>[email protected]</a>

Hanna Ögren                        +45 3079 8519       <a href=”mailto:[email protected]”>[email protected]</a>

Anders Mikkelsen                +45 3079 4461       <a href=”mailto:[email protected]”>[email protected]</a>

Kasper Veje (US)                 +1 609 235 8567     <a href=”mailto:[email protected]”>[email protected]</a>

 

<em>Glooko Investors:</em>

Michelle de Haaff                +1 650 720 5310   <a href=”mailto:[email protected]”>[email protected]</a>

 

PRM 0301 Rev A

FREE Webinar on October 24, 2016 provides an overview of their digital diabetes program powered by Glooko

Mountain View, California and Gothenburg, Sweden –October 21, 2016 – Atrius Health has always been an innovator when it comes to providing services to their patients. They are a national leader in clinical quality and electronic patient record use, and are a Pioneer Accountable Care Organization with approximately 75% of their revenue generated through risk based contracts.  Atrius Health has successfully implemented Glooko as their diabetes remote patient monitoring solution, which includes an integration with their electronic health record (EHR) system.

“For us, Glooko provides the ability to enable our teams to easily provide remote support to the patients we serve with diabetes,” said Dr. Michael Lee, Senior Medical Director of Clinical Informatics at Atrius Health. In a recent program using Glooko, Atrius Health saw positive outcomes for people with gestational diabetes. Using Glooko, they were able to more effectively manage and support women diagnosed with diabetes while pregnant.

Dr. Lee continues, “Glooko makes it easy for patients to capture their diabetes, exercise, diet and medication data and immediately share that with our population health staff allowing us to provide preventative and in-between visit care to optimize the care plan and prevent acute situations.”

In a webinar on October 24, 2016, Atrius Health will discuss how they use the Glooko Population Health Management and Mobile Health system to better serve people with diabetes.

Jennivine Lee Simon, Director of Marketing at Glooko will be joined by Dr. Michael Lee, Senior Medical Director of Clinical Informatics at Atrius Health to discuss why Atrius decided to implement remote patient monitoring, how they selected Glooko, the EHR integration process and their lessons learned.  This webinar will also include a live Q&A session with Dr. Lee.

Link here to register to attend this FREE webinar. Those who register will also gain access to a recording of the event.

About Glooko
Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offer diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at www.glooko.com and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko.
©2016 Glooko, Inc. Glooko is a trademark of Glooko, Inc. Other brand names may be trademarks of their respective owner(s). Information is subject to change without notice. All rights reserved.

Partnership provides bring your own device ‘BYOD’ virtual care solution to patients with diabetes

New York, New York and Mountain View, California – July 7, 2016 – AMC Health, the leading provider of proven remote patient monitoring and engagement solutions that are exclusively endorsed by the American Hospital Association, and Glooko Inc., the leading population health platform for diabetes management, today announced a partnership to help clinicians and patients improve diabetes outcomes at lower costs.

Glooko is one of many FDA 510(k) cleared devices now integrated into AMC Health’s expanding FDA-cleared CareConsole® virtual care platform. Glooko is currently being used in 1,000+ health systems, health plans and employers in the USA, including Joslin Diabetes Center, Stanford Health, and Atrius  Health in Boston. Glooko’s HIPAA-compliant solution enables easy downloading of information from over 50 of the most popular blood glucose meters, insulin pumps, and continuous glucose monitors (CGMs). Glooko enables individuals to download and add context to their data through its award-winning diabetes mobile application. Adding Glooko to the AMC Health CareConsole® platform with robust decision support analytics provides healthcare organizations tools to better optimize their clinical impact in diabetes populations.

“Glooko will be joining AMC Health’s extensive ecosystem of healthcare technology partners that have chosen to integrate into AMC Health’s CareConsole® virtual care platform. This partnership with Glooko will give patients the flexibility of using their existing glucometers and support stronger connections with their clinical teams on a real-time basis, while also expanding care beyond the walls of hospitals, doctors’ offices and outpatient settings,” said Nesim Bildirici, founder and CEO of AMC Health. “Our clinically proven solutions, and clinical, technology and analytics expertise, gained over millions of patient days, ensure that our solutions promote patient engagement, improve patient outcomes, and prevent costly acute episodes.”

AMC Health has been performing groundbreaking work in remote patient monitoring and engagement since its founding in 2002, and has consistently partnered with organizations to assist with the identification of patients with the highest risks, likelihood of hospitalizations, and utilization of services. AMC Health has demonstrated, in peer-reviewed clinical studies , that its remote patient monitoring and engagement solutions have reduced hospital readmissions for patients with heart failure and reduced their cost of care. AMC Health solutions have also helped patients with diabetes significantly reduce their HbA1c levels and patients with hypertension substantially reduce and control their blood pressure. These results have been published in the Journal of the American Medical Association (JAMA), Journal of Managed Care Medicine , Medical Care and Population Health Management.

“Glooko’s partnership with AMC Health means health systems, health plans, and employers will be able to ramp diabetes-focused programs using Glooko more quickly by leveraging AMC Health’s remote monitoring & population management expertise” said Rick Altinger, Glooko’s CEO. “Organizations using AMC Health’s suite of disease management tools addressing heart disease, hypertension and obesity can now access Glooko’s best-in-class platform for remotely monitoring blood glucose, a key biometric in managing those conditions.”

About AMC Health
AMC Health is the leading provider of virtual care solutions. AMC Health customers use these proven solutions to promote patient engagement, improve patient outcomes, and prevent costly acute episodes. AMC Health’s FDA-cleared remote patient engagement solution is powered by CareConsole®, an open web-based platform, which integrates seamlessly with biometric monitoring devices and other technologies so a care team can monitor patients’ chronic conditions and adherence to a care plan wherever they might be. Our customers have demonstrated through large published peer-reviewed studies across various disease states that outcomes can be improved significantly through connecting patients to their clinical teams on a real-time basis and expanding care beyond the walls of hospitals, doctors’ offices and outpatient settings. The published studies highlight improved care management, reduced medical costs and hospital readmissions, and a 3:1 or greater return on investment. AMC Health’s remote patient monitoring and engagement solutions have earned the exclusive endorsement of the American Hospital Association. For more information, visit www.amchealth.com.

About Glooko
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at https://glooko.com, and follow us at twitter.com/GlookoInc and facebook.com/Glooko.

Tweet this: @AMCHealth and @GlookoInc partnership provides #BYOD #virtualcare solution to improve diabetes outcomes | #remotepatientmonitoring #telehealth

Contacts:
Tanya L. Travers
917-757-9751
[email protected]
Vikram Singh
925-487-1461
[email protected]

Upon release Medtronic users and clinicians will have access to retrospective data insights from their Medtronic devices using Glooko’s Mobile and In-Clinic Apps

Mountain View, Calif. – June 10, 2016 – Glooko Inc., the leading unified platform for diabetes management, today announced compatibility with Medtronic MiniMed ® insulin pumps and sensors. Glooko will demonstrate the integrated solution at the 76th Annual Scientific Sessions of the American Diabetes Association from June 10 – 13, 2016 in New Orleans. The integrated solution highlights optimized workflows for both patients and clinics in downloading data from Medtronic insulin pumps and continuous glucose monitoring (CGM) sensors. In addition, it offers the ability to analyze the correlation of insulin data with blood glucose readings from over 50+ blood glucose meters, continuous glucose monitors (CGMs) as well as from exercise and biometric devices.

“By integrating into the Glooko diabetes management platform, we now provide safe and secure access to meaningful diabetes information, beyond just device data, and new disease management solutions. Our partnership with Glooko reflects our overall strategy to become a holistic diabetes management company and provide new solutions for people with diabetes, for greater freedom and better health,” said Annette Brüls, President of Diabetes Service and Solutions at Medtronic.

Glooko is the first mHealth and Remote Patient Monitoring diabetes platform compatible with Medtronic insulin pumps and sensors. Glooko makes this data available for people with diabetes (PWDs) to use and analyze on the go via the Glooko Mobile App by enabling users to seamlessly access their data in Glooko on their iOS and Android phones. Glooko enables clinics to sync popular diabetes devices and analyze glucose, insulin, exercise and diet trends via the Glooko Office Kiosk, enabling improved engagement with PWDs during their office visits. Glooko also makes it easy for care teams to remotely support Medtronic patients through the Glooko Population Tracker, which provides them with on-demand remote access to patient data in between visits.

“Providing users of Medtronic insulin pumps and sensors, with retrospective insights about their insulin dosing and its impact on their glucose levels on their phone can make a real difference in their overall health and outcomes,” said Rick Altinger, CEO of Glooko.

He continues, “Being the first to deliver a remote patient monitoring and mobile health solution that includes Medtronic data provides the patient population with a capability that can really have an impact.”

Glooko’s Medtronic-integrated release includes:

Glooko plans to make this integration generally available in July of 2016. Glooko will be offering a limited time promotion to purchase a discounted version of the Glooko Kiosk with Medtronic support. To sign up for the promotion, click here . Once available, Medtronic users can simply download the Glooko Mobile App from the iOS or Android App Store to get started.

Contact Glooko for more information about how you can get the Glooko Patient Mobile App or Glooko Office Kiosk for in-clinic download and analysis of Medtronic Insulin Pumps and Sensors and 50+ other devices.

MiniMed® and CareLink® are registered trademarks of Medtronic plc .

ABOUT GLOOKO
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at https://glooko.com, and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko.

New offering includes Glooko Personal Advisor which automatically identifies patterns for individuals and Glooko Clinical Advisor, for facilitating clinician-managed decision support during and between in-clinic visits

Mountain View, Calif. – June 10, 2016 – Glooko Inc., the leading unified platform for diabetes management, today announced its new ‘Glooko Advise’ product line, including ‘Glooko Personal Advisor’ and ‘Glooko Clinical Advisor,’ which enables both people with diabetes (PWDs) and clinicians with practical diabetes decision support. Glooko will demonstrate the new product functionalities at the 76th Annual Scientific Sessions of the American Diabetes Association from June 10 – 13, 2016 in New Orleans.

Glooko Personal Advisor aims to help PWDs better understand their retrospective diabetes data and improve daily decisions by using proprietary pattern recognition algorithms to recognize trends and deliver targeted educational content based on those trends. Personal Advisor will identify numerous trends including PWDs’ ‘Best Day’, the ‘Time of Day’ when glucose runs high or low, and ‘Summary Statistics’ that recognizes improvements or regressions in the Average BG and frequency of highs, lows, and in range readings.

“Providing this immediately understandable and novel approach for describing and interacting with diabetes data can truly illuminate learnings for people with diabetes to help them achieve their personal goals,” said Dr. David Kerr, Director of Research and Innovation at the William Sansum Diabetes Center in Santa Barbara. He continued, “without doubt the new Glooko Advise product line provides valuable and relevant tools for people with diabetes and their clinicians that will enable the achievement of the desired outcomes in diabetes care.”

Glooko Clinical Advisor will include both AACE guidelines and clinical algorithms that, once initialized and approved by a clinician, can aid the clinician to more effectively optimize diabetes therapy in the weeks or months between in-clinic appointments. Glooko will demonstrate products within Clinical Advisor that enable:

1. Mobile Insulin Dosing – Using Glooko’s Mobile Insulin Dosing system (MIDS), clinicians can configure an insulin prescription for PWDs starting on long-acting insulin using a standard or custom insulin titration method based on the AACE guidelines. After the configuration, Glooko’s Mobile App will automatically prompt, recommend and remind PWDs of insulin adjustments based on glucose readings and the insulin titration configuration defined by their clinician.

2. Insulin Pump Settings Adjustments – Glooko’s first built-in 3rd party algorithm developed by DreaMed Diabetes recommends adjustments to critical insulin pump settings, including basal rates and insulin-to-carb ratios. Through the Glooko interface and leveraging Glooko’s easy data syncing and management platform, clinicians can review DreaMed algorithm recommendations and make therapeutic regimen decisions. Within a patient record in the Glooko Population Tracker, the clinician can approve, adjust, or prevent the recommendations from being delivered to the patient.

“With the Glooko Advise product line we are executing our vision around personalized medicine where we aim to deliver improved daily decision support for people with diabetes and the teams who care for them. Clinicians clearly need additional tools to allow them to deliver more efficient care in order to handle the increasing number of PWDs on long acting insulin – Glooko’s Mobile Insulin Dosing System will meet this need” said Rick Altinger, CEO of Glooko.

DreaMed will deliver algorithms for Pump Settings adjustments by building on Glooko’s Application Programming Interfaces (APIs), which partner companies can leverage for offering FDA-regulated algorithms within Glooko Clinical Advisor. Funding for the development of this first integrated algorithm comes from a grant from the Helmsley Charitable Trust , announced earlier this year. The grant aims to facilitate and optimize insulin pump care for people with Type 1 diabetes.

Glooko Personal Advisor will be available in July 2016. The components of Glooko Clinical Advisor will be deployed for clinical studies in the second half of 2016. For more information, contact Glooko.

ABOUT GLOOKO
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at https://glooko.com , and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko .

DreaMed Diabetes leverages Glooko diabetes management platform to deliver proprietary insulin dosing algorithms to clinicians and people with diabetes

February 3, 2016 – Palo Alto, CA and Petah Tikva, Israel – Glooko, Inc., provider of the leading unified platform for diabetes management, and DreaMed Diabetes, developer of innovative and patient-centric decision support technologies for insulin-dependent people with diabetes (PWDs), today announced a partnership to commercialize DreaMed’s Advisor algorithm using the Glooko platform. The partners will demonstrate the integrated solution at the Advanced Technologies & Treatments for Diabetes (ATTD) conference, from 3 – 6 February 2016 in Milan, Italy.

Glooko and DreaMed aim to vastly improve insulin management for over 30 million people with Type 1 diabetes globally [1], about 35% of whom currently use insulin pumps [2]. Glooko’s diabetes platform enables a PWD to download and visualize data from their diabetes device using their mobile phone and makes this data available to clinicians via the secure cloud. With the integration of DreaMed’s MD – Logic Pump Advisor into Glooko’s platform, insulin pump data can be assessed for patterns that yield personalized recommendations for critical pump-related settings, including basal rates and insulin-to-carb ratios. These recommendations are made available to clinicians via Glooko’s Population Management application, which allows a review of the therapeutic basis behind the recommended adjustment. Once approved, the recommendations are made available via the Glooko app on the PWD’s mobile phone.

For Glooko, the collaboration with DreaMed Diabetes is an initial step towards the company’s broader initiative to cultivate an ‘app store for diabetes algorithms and tools’, all of which leverage Glooko’s robust diabetes data engine and mobile app/web capabilities. “Clinicians, mathematicians, and data engineers from universities and companies worldwide have been developing algorithms capable of using diabetes data to micro-optimize each component of diabetes management, from insulin pump settings to dietary choices” said Rick Altinger, Glooko CEO. He continued, “Enabling partners to use Glooko’s vast diabetes dataset to deliver personalized insights at the patient level will give clinicians the information they need to provide impactful recommendations that can improve health outcomes.”

By allowing diabetes decision support tools to be built on the Glooko platform, the company is carving a path for PWDs and clinicians to get access to innovative technology to help improve their overall decision making. At the same time, Glooko provides a scalable way to enable organizations that create these algorithms to test, improve and ultimately commercialize them, bringing innovation to the forefront of positively impacting the lives of people with diabetes.

DreaMed CEO, Eran Atlas, said “We are very gratified to be collaborating with Glooko on the first commercialization project for our Advisor technology. Together, we will transform critical diabetes data into actionable information, giving healthcare providers a clinically effective, patient-specific decision support tool. Our collaboration is designed to raise the bar for fast, efficient and personalized medicine, by providing both doctors and diabetes patients with a holistic, simple glucose balancing solution.”

The partnership with Glooko is part of DreaMed’s overall strategy to transform Advisor into a necessary analytical component in any diabetes management system offering advanced personalized medicine. Future collaborations will include partnering with stakeholders that generate, collect and store patient data, to provide real-time glucose balance and behavioral guidance. Such collaborations can transform collected data into actionable information, with the aim of enabling DreaMed partners to provide more holistic and simple solutions for diabetes patients.

[1] IDF Diabetes Atlas – Sixth Edition

[2] T1D Exchange – Insulin Pump Use Varies Across Globe Despite Benefits in Diabetes Control

ABOUT GLOOKO
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 40 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at https://glooko.com , and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko .

ABOUT DREAMED DIABETES
DreaMed Diabetes, established in 2014, is dedicated to empowering insulin-dependent patients and their doctors with innovative and patient-centric decision support technology. The DreaMed Diabetes team includes thought-leading endocrinologists, biomedical engineers, and software developers with more than 50 years of combined field experience. With its innovative multidisciplinary approach, DreaMed Diabetes developed MD – Logic Technology – sophisticated algorithms which analyze available real-world data on dosing and glucose levels, in addition to patient reporting, emulating the way expert endocrinologists actually evaluate their patients. DreaMed became the first company in the world to receive CE Mark approval for artificial pancreas technology (Glucositter), as well as the first to conduct artificial pancreas studies under real-world conditions. DreaMed is bringing optimal glycemic control to patients with diabetes everywhere, with personalized medicine that improves their quality of life and lowers their overall treatment costs. Learn more at http://www.dreamed – diabetes.com and follow us at Twitter.com/DreaMedDiabetes.

Recent results on the effectiveness of Glooko-enabled Patient Remote Monitoring and Diabetes Self-Management Presented on October 22, 2015 at the Diabetes Technology Meeting

Thursday, Oct 29, 2015 – Palo Alto, CA – Glooko, the leading unified platform for diabetes management, today  announced that Glooko was featured in a poster presentation on the effectiveness of Glooko-enabled Type 2 diabetes management resulting from a pilot conducted at the Diabetes & Glandular Disease (DGD) Clinic. Based in San Antonio, Texas, DGD is the one of the largest Type 2 adult endocrinology facilities in the country. The presentation, given by Dr. Jerome Fischer, a partner and Endocrinologist at DGD, occurred during the scientific poster session at the Diabetes Technology Meeting on October 23, 2015 in Bethesda, MD.

The twelve-week pilot measured the effectiveness of using Glooko, which enables data-driven clinical interactions between clinician and patient via the Glooko mobile app and Glooko Population Tracker, to facilitate remote monitoring and coaching of Type 2 patients by nurse practitioners at DGD (intervention group). The intervention group was compared with a control group in which Type 2 patients used Glooko alone for diabetes self management (along with treatment as usual).

Both the intervention and control groups experienced a statistically significant improvement in mean blood glucose and glycemic variability. Notably, subjects who experienced three or more Glooko-facilitated remote clinical interactions with a nurse practitioner experienced a significantly better improvement in mean blood glucose compared to control subjects.

In a post-pilot survey, 96% of responding subjects said Glooko made it easier to adhere to their diabetes therapy regimen. In addition, 81% of responding subjects reported receiving therapy recommendations during their remote clinical interactions; these interactions regularly included insulin and medication adjustments. “Improving the quality, frequency and cost of clinical interactions between the clinician and patient is crucial for optimizing diabetes management,” said Rick Altinger, Glooko CEO. For information on pilot results or a copy of the poster presentation, contact [email protected].

About Glooko
Glooko is the Unified Platform for Diabetes Management and provides an FDA-cleared, HIPAA-compliant Web and Mobile application for diabetes patients and clinicians which improves outcomes and lowers costs. The platform seamlessly unifies data from over 50 of the leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and pattern-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc , and Facebook.com/Glooko .

Glooko PR
Contact
Vikram Singh
[email protected]

Integration enables wireless download of blood glucose data for on-demand insights and alerts

Palo Alto, Calif. – September 24 , 2015 – Glooko Inc., the leading unified platform for diabetes management, today announced general availability of its integration with Roche ’s Accu-Chek Aviva Connect blood glucose meters to send blood glucose (BG) results automatically to the Glooko platform. Through wireless Bluetooth Smart technology built into these Accu-Chek Aviva Connect meters, the release enables near real-time syncing of blood glucose data to the Glooko platform without the need to connect cables. Data syncing happens in the background directly after blood glucose readings are measured by people using an Accu-Chek Aviva Connect meter.

With this latest integration, Glooko addresses a long-standing deterrent to tracking blood glucose trends: manual entry and syncing of blood glucose data into apps and disease management systems to help patients and clinicians better manage diabetes. When people with diabetes use a Bluetooth enabled Accu-Chek Aviva Connect meter, they simply have to check their blood glucose and their data becomes automatically available in Glooko, where it is combined with exercise, diet, CGM, pump and medication data in a series of reports and analytics.

Traditional mobile health solutions that require manual entry of BG data have struggled to capture accurate data and keep users engaged, resulting in missing data points and an inability to review accurate glucose trends necessary for diabetes decision making. With its support for Accu-Chek Aviva Connect meters, Glooko builds on its device-agnostic platform, which is focused on making diabetes management easier through data accessibility and advanced analytics.

“We are excited that Glooko has chosen to add the Accu-Chek Aviva Connect meter to its platform”, said Laura Spiegel, Group Marketing Manager of Strategy and Innovation at Roche Diagnostics Corporation. “By adding our Bluetooth enabled meter to its lineup, Glooko is able to leverage seamless access to blood glucose data in order to deliver actionable information that is accessible near real time. Individuals using Accu-Chek Aviva Connect can easily share this information with their care team to support better decisions and care adjustments for positive health outcomes.”

With this new integration to the Glooko platform, a patient’s family members and their care team can use the Glooko mobile and web apps to remotely monitor their blood glucose as well as other important information, such as insulin, carb and fitness data in a single platform. The patient’s care team can also access this information and connect with patients who require more attention. “ In situations where a patient is experiencing dangerous hypoglycemic events, Roche’s seamless transfer of blood glucose data through Glooko in near real time to the smartphone triggers Glooko to engage patients in creating better hypoglycemic awareness via the Joslin HypoMap™ survey and other pattern recognition features, giving patients and their care teams the ability to actively mitigate these issues,” said Michelle de Haaff, Glooko’s Vice President of Marketing.

To learn more about what blood glucose, pump, CGM, exercise and mobile devices that Glooko integrates with, visit our website compatibility page.

The Accu-Chek Aviva Connect meter can found exclusively at Walgreens nationwide.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For 40 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. For more information: www.accu-chek.com .

All trademarks used or mentioned in this release are legally protected.

About Glooko
Glooko is the Unified Platform for Diabetes Management and provides an FDA-cleared, HIPAA-compliant Web and Mobile application for diabetes patients and clinicians, which aims to improve outcomes and lowers costs. The platform seamlessly unifies data from over 50 leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offers diabetes-centric analytics and supplies insightful reports, graphs and pattern-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc  and Facebook.com/Glooko .

Press Contact:
Vikram Singh
[email protected]

Medical advisory board charged with helping to advance the Glooko unified diabetes management platform and advise Glooko on clinical studies

Palo Alto, Calif. ​ – July 9, 2015 ​ – ​Glooko Inc​., the leading unified platform for diabetes management, today announced the formation of its first Medical Advisory Board who will provide Glooko with clinical expertise in the area of diabetes analytics and clinical studies.

Comprised of a highly accomplished group of physicians from leading institutions across the United States, the Medical Advisory Board will share their extensive expertise in clinical engagement, diabetes devices, patient outcomes analytics, population management and other areas important to Glooko’s clinical studies, product development and strategic initiatives.

“As Glooko continues to deliver a unified platform for diabetes management, ​this board will be central in helping us to continue to deliver clinically relevant insights and outcome studies to drive increasing value to Provider Health Systems and the patients they serve”, said Rick Altinger, Glooko, CEO.

He continued, “We are thrilled by both the expertise and caliber of the members of our newly formed medical advisory board. Their complementary backgrounds and experiences, coupled with their expertise and innovative approaches to clinical practice will help to keep Glooko on the cutting edge.”

The five ­member board, chaired by Glooko’s Chief Medical Officer, Dr. Michael Greenfield, includes:

Dr. Mark Clements, MD, PhD -​ Associate Professor of Pediatrics, University of Missouri-­Kansas City School of Medicine, Children’s Mercy Hospitals, Kansas City, MO
Specializing in glucose variability, diabetes care technology and chronic complications in diabetes, Dr. Clements, MD, PhD and AAP fellow, brings a passion for data analytics and insights to his pediatric endocrinology practice at Children’s Mercy Hospitals and is known as a diabetes care innovator for the children he treats.

Dr. Jerome Fischer, MD­ – Diabetes and Glandular Disease Clinic (DGD), Clinical Instructor, University of Texas Health Science Center, San Antonio, TX

An accomplished researcher, partner and CIO of the DGD Clinic in San Antonio, TX, Dr. Fischer, MD has been involved as investigator in numerous research trials and is considered a leader in the most progressive use of diabetes education combined with technology and cutting-­edge treatments to serve diabetes patients in Southern Texas.

Dr. Michael Greenfield, ​MD -­ Glooko Chief Medical Officer, Endocrinologist, El Camino Hospital, Palo Alto, CA

Glooko Chief Medical Officer and diabetes technology expert, Dr. Greenfield, MD helps to lead the Glooko effort to create patient and clinical relevant and innovative analytics. Dr. Greenfield chairs the IRB at El Camino Hospital in Silicon Valley, completed his endocrine training at Stanford and is an accomplished researcher and a beloved clinician.

Dr. David Kerr, MD – Director of Diabetes Research and Innovation, Sansum Diabetes Research Institute, Santa Barbara, CA
Dr. David Kerr, MD is a UK trained physician and endocrinologist, a former diabetes ​ researcher at Yale and the former Editor of the Journal of Diabetes Science and Technology. Dr. Kerr is a Fellow of the Royal College of Physicians of Edinburgh, visiting Professor at Bournemouth University and has held a Gold Clinical Excellence Award from the National Health Service in the UK.

Dr. Howard Wolpert, MD -­ Director, Institute for Technology Translation, Joslin Diabetes Center & Associate Professor, Harvard Medical School, Boston, MA
A world­-renowned diabetes researcher and clinician, Dr. Howard Wolpert, MD has focused on the use of technology in intensive diabetes management. He established and directed the Insulin Pump & Continuous Glucose Monitoring Programs at the Joslin Clinic, and had been principal investigator in several multi­center randomized controlled trials. He is one of two foreign members of the Scientific Advisory Board of the European Union­-funded academic/industry collaborative on diabetes technology.

As Glooko’s international expansion continues we look forward to inviting several international thought leaders from around the globe to join the Glooko Medical Advisory Board.

With the decline of board certified endocrinologists, coupled with projected increases in diabetes population growth, the ability to care for diabetes patients is more and more falling on primary care and family care physicians. Through Glooko’s Population Management and Office Kiosk applications, endocrinologists and primary care physicians will have the data and insights they need to more efficiently and effectively treat patients with Type 1, Type 2 and gestational diabetes, enabling them to scale quality delivery of medical services, improve overall diabetes outcomes and ultimately lower the overall cost of serving the diabetes population.

This announcement comes on the heels of Glooko’s ​recent Series B investment ​that brought $16.5M of additional funds into the business. The investment will be used to fuel expansion of the Glooko platform to include device data from insulin pumps, continuous glucose monitoring systems and integration of personalized predictive algorithms that enable both patient and provider decision support.

About Glooko
Glooko is the ​Unified Platform for Diabetes Management ​and provides an FDA-­cleared, HIPAA­-compliant Web and Mobile application for diabetes patients and clinicians which improves outcomes and lowers costs. The platform seamlessly unifies data from over 50 of the leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes­-centric analytics and supplies insightful reports, graphs and pattern­-triggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at​ https://glooko.com and follow us at ​Twitter.com/GlookoInc, and Facebook.com/Glooko.

Glooko PR Contact
Vikram Singh
[email protected]

Medtronic Aims to Provide People with Diabetes, Their Care Teams and Healthcare Providers with Greater Insights to Improve Care

BOSTON – June 5 , 2015 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an agreement with Glooko, the trusted leader in diabetes data unification and analytics, to improve access to meaningful diabetes health data in a safe and secure way. The partnership will incorporate information from Medtronic insulin pumps and continuous glucose monitors (CGM) into Glooko’s secure, unified, cloud and mobile-based diabetes management platform. In addition, Medtronic will be able to integrate other health and wellness data sources, such as food, medication, fitness and biometric data with its CareLink platform. Combining this with insulin and CGM data could provide additional insights for patients and providers and could be beneficial to improve diabetes management.

Medtronic aims to provide holistic diabetes management solutions that optimize both clinical outcomes and health economics, which will rely on the safe and secure sharing of diabetes data across the care continuum. Both companies are exhibiting at American Diabetes Association 75th Scientific Sessions: Medtronic at Booth #437 and Glooko at Booth #104.

Medtronic’s decision support software, CareLink, has provided an incredible amount of compelling diabetes data along with an understanding of diabetes care pathways. Now, in addition to viewing insulin and glucose data through Medtronic’s Carelink system, people with diabetes and their healthcare providers will also be able to access this information through Glooko, who will integrate it with other health data to offer a unified view to patients and their care teams to better make both day-­to-day and longer term decisions. Glooko leverages mobile and web based views to organize all the information into consolidated analytics and insights that enable patients and healthcare providers to understand the impact of carbs and insulin, combined with other variables like exercise and biometric data.

“Our goal is to provide people with diabetes, their care teams and healthcare providers with actionable insights that improve decision-making to optimize care. By partnering with the Glooko diabetes management platform, we can provide safe and secure access to meaningful diabetes information to our customers that goes beyond just device data,” said Annette Brüls, vice president and general manager, Diabetes Services and Solutions at Medtronic. “ Combining the additional data collected by Glooko with our CareLink data will enable further insights into how various health and fitness activities affect insulin therapy. The Glooko partnership is part of our overall strategy to move towards a holistic diabetes management company and use our leading technologies, data and informatics to enable better therapy decision making and care for people with diabetes, to enable greater freedom and better health.”

“Medtronic customers and their healthcare teams can leverage the Glooko unified platform to improve outcomes and reduce costs by leveraging mobile and cloud based technology to better understand and act on insights to improve their care plan and lifestyle,” said Rick Altinger, CEO of Glooko. “Working together we will bring information from Medtronic insulin pumps and continuous glucose monitors, along with food, medication, fitness and biometric data, to offer a unified view and actionable insights to patients and their care teams.”

With Medtronic data available in the Glooko diabetes management platform, healthcare systems will be able to provide more proactive care across the broadest set of patients. Glooko will also allow healthcare systems to identify blood glucose patterns that represent actions that can be improved (such as altering insulin bolus levels) or flagging at-risk patients among their patient population.

About Glooko
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 30 blood glucose meters, the world’s major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and API’s offers diabetes-centric analytics and supplies insightful reports, graphs and risk flags to health systems and payers. Learn more at https://glooko.com and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko .

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is the global leader in medical technology–alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronicʹs periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.